Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Learn how GA4GH helps expand responsible genomic data use to benefit human health.
Our Strategic Road Map defines strategies, standards, and policy frameworks to support responsible global use of genomic and related health data.
Discover how a meeting of 50 leaders in genomics and medicine led to an alliance uniting more than 5,000 individuals and organisations to benefit human health.
GA4GH Inc. is a not-for-profit organisation that supports the global GA4GH community.
To guide our collaborative, globe-spanning alliance, GA4GH relies on a Standards Steering Committee and an Executive Committee.
The Funders Forum brings together organisations that offer both financial support and strategic guidance.
The EDI Advisory Group responds to issues raised in the GA4GH community, finding equitable, inclusive ways to build products that benefit diverse groups.
Distributed across four Host Institutions, our staff team supports the mission and operations of GA4GH.
Curious who we are? Meet the people and organisations across six continents who make up GA4GH.
More than 500 organisations connected to genomics — in healthcare, research, patient advocacy, industry, and beyond — have signed onto the mission and vision of GA4GH as Organisational Members.
These core Organisational Members are genomic data initiatives that have committed resources to guide GA4GH work and pilot our products.
This subset of Organisational Members whose networks or infrastructure align with GA4GH priorities has made a long-term commitment to engaging with our community.
Local and national organisations assign experts to spend at least 30% of their time building GA4GH products.
Anyone working in genomics and related fields is invited to participate in our inclusive community by creating and using new products.
Wondering what GA4GH does? Learn how we find and overcome challenges to expanding responsible genomic data use for the benefit of human health.
Study Groups define needs. Participants survey the landscape of the genomics and health community and determine whether GA4GH can help.
Work Streams create products. Community members join together to develop technical standards, policy frameworks, and policy tools that overcome hurdles to international genomic data use.
GIF solves problems. Organisations in the forum pilot GA4GH products in real-world situations. Along the way, they troubleshoot products, suggest updates, and flag additional needs.
NIF finds challenges and opportunities in genomics at a global scale. National programmes meet to share best practices, avoid incompatabilities, and help translate genomics into benefits for human health.
Communities of Interest find challenges and opportunities in areas such as rare disease, cancer, and infectious disease. Participants pinpoint real-world problems that would benefit from broad data use.
See all our products — always free and open-source. Do you work on cloud genomics, data discovery, user access, data security or regulatory policy and ethics? Need to represent genomic, phenotypic, or clinical data? We’ve got a solution for you.
All GA4GH standards, frameworks, and tools follow the Product Development and Approval Process before being officially adopted.
Learn how other organisations have implemented GA4GH products to solve real-world problems.
Help us transform the future of genomic data use! See how GA4GH can benefit you — whether you’re using our products, writing our standards, subscribing to a newsletter, or more.
Help create new global standards and frameworks for responsible genomic data use.
Align your organisation with the GA4GH mission and vision.
Solve your real-world data problems with support from this valuable network of global institutions.
Work with like-minded groups committed to better data use in areas like rare disease, cancer, and infectious disease.
Share your thoughts on all GA4GH products currently open for public comment.
Solve real problems by aligning your organisation with the world’s genomics standards. We offer software dvelopers both customisable and out-of-the-box solutions to help you get started.
Learn more about upcoming GA4GH events. See reports and recordings from our past events.
Speak directly to the global genomics and health community while supporting GA4GH strategy.
Be the first to hear about the latest GA4GH products, upcoming meetings, new initiatives, and more.
Questions? We would love to hear from you.
Read news, stories, and insights from the forefront of genomic and clinical data use.
Attend an upcoming GA4GH event, or view meeting reports from past events.
See new projects, updates, and calls for support from the Work Streams.
Read academic papers coauthored by GA4GH contributors.
Listen to our podcast OmicsXchange, featuring discussions from leaders in the world of genomics, health, and data sharing.
Check out our videos, then subscribe to our YouTube channel for more content.
View the latest GA4GH updates, Genomics and Health News, Implementation Notes, GDPR Briefs, and more.
Discover all things GA4GH: explore our news, events, videos, podcasts, announcements, publications, and newsletters.
22 Aug 2020
GEnome Medical alliance Japan (GEM Japan), a Driver Project of the Global Alliance for Genomics and Health (GA4GH), has released GEM Japan Whole Genome Aggregation (GEM-J WGA) — a first-of-its-kind open-access variant frequency panel of 7,609 Japanese whole genome sequences.
GEnome Medical alliance Japan (GEM Japan), a Driver Project of the Global Alliance for Genomics and Health (GA4GH), has released GEM Japan Whole Genome Aggregation (GEM-J WGA) — a first-of-its-kind open-access variant frequency panel of 7,609 Japanese whole genome sequences. Researchers at GEM Japan detected >76M autosomal single nucleotide variations（SNV) and >10M autosomal insertion and deletion (INDEL) sequences in the dataset. They detected another >2M SNVs and >400K INDELs on the X chromosome.
The Japan Agency for Medical Research and Development (AMED) established GEM Japan in 2018 to facilitate genomic and health data sharing among research and medical laboratory communities, both domestically and internationally. GEM Japan aggregates genotypic and associated phenotypic information from various Japanese disease-specific and population genetic studies into publicly available resources based on a standardized format.
“GEM-J WGA has been much encouraged by GA4GH to share Japanese allele frequency data, including rare variants of 0.01%, as a global reference to the Asian ethnic specificity,” said Hidewaki Nakagawa, M.D., Ph.D., Program Officer at AMED and the GEM Japan Driver Project Champion at GA4GH. “Our participation in GA4GH has motivated us to pursue this work through its focus on the value of ethnically diverse genomic data.”
“In the GA4GH community, GEM Japan has become well recognized as the global leader in sharing Asian-specific data to facilitate the interpretation of human diseases and improve medical practice — not only in Japan but also around the world,” said Ewan Birney, Ph.D., Director of EMBL’s European Bioinformatics Institute and Chair of the GA4GH Steering Committee. “This selfless gift from Japan to the world will ensure that people of Japanese descent around the globe will benefit from genomic research.”
GEM Japan has established a nation-wide alliance of universities, institutes, and hospitals committed to the promotion of genome-based medicine. Patient information and genomic data are securely collected and used in research to investigate pathogenic variations, risk factors, and biomarkers. The GEM-J WGA is the culmination of a collaborative collection and analysis effort among this alliance, including researchers at Tohoku Medical Megabank Organization (ToMMo) at Tohoku University, Iwate Tohoku Medical Megabank Organization (IMM) at Iwate Medical University , RIKEN, and The Institute of Medical Science at The University of Tokyo (BBJ) .
The data were released through TogoVar, a database developed by the National Bioscience Database Center (NBDC) at the Japan Science and Technology Agency (JST) and Database Center for Life Science (DBCLS), Joint Support-Center for Data Science Research at Research Organization of Information and Systems. Based on the Genome Aggregation Database (gnomAD) project, TogoVar is an integrated database of Japanese genomic variation. The resulting Japanese gnomAD data will be clinically valuable for “filtering out” rare but presumably non-pathogenic variants.
Individual genome sequences mapped to reference genome sequences will also be made available under controlled-access / group-sharing through the Japanese Genotype-phenotype Archive (JGA) and AMED Genome group sharing Database (AGD), operated in collaboration with the Bioinformation and DNA Data Bank of Japan (DDBJ) Center at the National Institute of Genetics and NBDC at JST.
“Summarized information on pathogenic or benign variants will also be made available in a standardized format that will be compatible with existing GA4GH activities, such as ClinVar,” said Nakagawa.
In particular, the information on pathogenic variations, which have been collected and curated on an upstream application such as the Patient Archive (PA), is integrated into the Medical Genomics Japan Variant Database (MGeND). MGeND consists of three types of formatted data:
GEM Japan is developing a standardized format for the three types of data and annotation. Our standards will be harmonized with existing GA4GH standards in our commitment to the Technical Work Stream.
Moreover, GEM Japan also provides use cases regarding “Localization,” with adding multi-lingual functions for Japanese users, such as phenotypic data collection captured with localized ontologies, and a good practice of data sharing from the viewpoint of a country where English is not the primary language.